A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. - Mooradian MJ; Reuben A; Prieto PA; Hazar-Rethinam M; Frederick DT; Nadres B; Piris A; Juneja V; Cooper ZA; Sharpe AH; Corcoran RB; Flaherty KT; et al. (Oncoimmunology, 2018)